Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIB Study of Subcutaneous Trastuzumab in HER2-Positive Early and Locally Advanced Breast Cancer
2013-001161-16Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Adverse events (safety and tolerability). Started Jul 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001161-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001161-16.